Literature DB >> 12766660

Magnesium chloride and ruthenium red attenuate the antiallodynic effect of intrathecal gabapentin in a rat model of postoperative pain.

Jen-Kun Cheng1, Yu-Jun Lai, Chien-Chuan Chen, Ching-Rong Cheng, Lih-Chu Chiou.   

Abstract

BACKGROUND: Gabapentin, a gamma-aminobutyric acid analog anticonvulsant, has been shown to possess antinociceptive effects in animal models and clinical trials. An endogenous binding site of [3H]gabapentin has been revealed to be the alpha(2)delta subunit of voltage-dependent Ca2+ channels. Magnesium chloride, ruthenium red, and spermine have been shown to modulate [3H]gabapentin binding to this binding site in vitro. In this study, the authors examined whether intrathecal magnesium chloride, ruthenium red, or spermine could affect the antiallodynic effect of intrathecal gabapentin in a rat model of postoperative pain.
METHODS: Under isoflurane anesthesia, male Sprague-Dawley rats received an incision over the plantar surface of the right hind paw to produce punctate mechanical allodynia. Withdrawal thresholds to von Frey filament stimulation near the incision site were measured before incision, 2 h after incision, and every 30 min after intrathecal coadministration of gabapentin with normal saline or different doses of magnesium chloride, ruthenium red, or spermine for 2 h.
RESULTS: Intrathecal gabapentin (30, 100, 200 microg) dose-dependently reduced incision-induced allodynia. Hexahydrated magnesium chloride (5, 10, 20 microg) and ruthenium red (0.2, 2, 20 ng) noncompetitively inhibited the antiallodynic effect of gabapentin. Spermine at doses not inducing motor weakness (30, 60 microg) did not affect the antiallodynic effect of gabapentin. The antiallodynic effect of intrathecal morphine (1.5 microg) was not affected by hexahydrated magnesium chloride (20 microg), ruthenium red (20 ng), or spermine (60 microg).
CONCLUSIONS: These results provide behavioral evidence to support that the alpha(2)delta subunit of Ca2+ channels may be involved in the antiallodynic action of intrathecal gabapentin in the postoperative pain model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766660     DOI: 10.1097/00000542-200306000-00026

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

1.  Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model.

Authors:  Matthew M Smiley; Ying Lu; Louis P Vera-Portocarrero; Amr Zidan; Karin N Westlund
Journal:  Anesthesiology       Date:  2004-09       Impact factor: 7.892

2.  Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery.

Authors:  Christophe Ménigaux; Frédéric Adam; Bruno Guignard; Daniel I Sessler; Marcel Chauvin
Journal:  Anesth Analg       Date:  2005-05       Impact factor: 6.627

3.  Electroacupuncture at 2/100 hz activates antinociceptive spinal mechanisms different from those activated by electroacupuncture at 2 and 100 hz in responder rats.

Authors:  Josie Resende Torres da Silva; Marcelo Lourenço da Silva; Wiliam Alves Prado
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-16       Impact factor: 2.629

4.  A comparison of intrathecal magnesium and ketamine in attenuating remifentanil-induced hyperalgesia in rats.

Authors:  Jiehao Sun; Hai Lin; Xiaona Feng; Jiaojiao Dong; Emmanuel Ansong; Xuzhong Xu
Journal:  BMC Anesthesiol       Date:  2016-09-06       Impact factor: 2.217

5.  Antinociceptive drug interaction between intrathecal vitamin E and gabapentin in the rat formalin test.

Authors:  Myoung-Joong Kim; Won Hyung Lee; Young-Kwon Ko; Boo Hwi Hong
Journal:  Korean J Anesthesiol       Date:  2012-11-16

6.  The Effect of Systemic and Regional Use of Magnesium Sulfate on Postoperative Tramadol Consumption in Lumbar Disc Surgery.

Authors:  Melek Demiroglu; Canan Ün; Dilsen Hatice Ornek; Oya Kıcı; Ali Erdem Yıldırım; Eyup Horasanlı; Semih Başkan; Emel Fikir; Mehmet Gamli; Bayazit Dikmen
Journal:  Biomed Res Int       Date:  2016-01-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.